No profile data available.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a listed company, based in South San Francisco, United States, with about 88 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$134.04 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $265.38 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
BridgeBio Oncology Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$265.38 million as of October 9, 2026.